Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IL2 | P60568 | 12/20 | 0.51 |
| ▸ | ABL1 | P00519 | 3/20 | 0.42 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.37 |
| ▸ | SIRT3 | Q9NTG7 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5555307 | 0.91 | IL2 (0.63) | IL2ABL1ALDH1A1 | |
| SCHEMBL5554369 | 0.88 | IL2 (0.51) | IL2ABL1 | |
| SCHEMBL15395772 | 0.87 | IL2 (0.55) | IL2ABL1 | |
| SCHEMBL5550529 | 0.86 | IL2 (0.49) | IL2ALDH1A1 | |
| SCHEMBL17092826 | 0.85 | IL2 (0.47) | IL2ABL1FGFR3 | |
| SCHEMBL5556181 | 0.83 | IL2 (0.47) | IL2ABL1 | |
| SCHEMBL15395851 | 0.83 | IL2 (0.51) | IL2ABL1 | |
| SCHEMBL8256822 | 0.83 | IL2 (0.46) | IL2ABL1ALDH1A1 | |
| SCHEMBL8259823 | 0.83 | IL2 (0.46) | IL2ABL1 | |
| SCHEMBL8252030 | 0.83 | IL2 (0.46) | IL2ABL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1848435-B1 | COMPOUNDS AGAINST INFLAMMATIONS AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP (US) | 2016-01-20 | — | — | EP | claimed |
| US-9090570-B2 | Compounds for inflammation and immune-related uses | PRCL Research Inc. (CA) | 2015-07-28 | — | — | US | claimed |
| US-20130309272-A1 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2013-11-21 | — | — | US | claimed |
| US-8518950-B2 | pyrazinyl, pyrimidinyl and pyridazinyl derivatives such asN-[5-(2-Chloro-5-trifluoromethyl-phenyl)-pyrazin-2-yl]-2,6-difluoro-benzamide, used as immunosuppressants for the treatmet or prevent inflammatory and immune disorders | SYNTA PHARMACEUTICALS CORP. (US) | 2013-08-27 | — | — | US | claimed |
| EP-1848435-A2 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | Synta Pharmaceuticals Corporation (US) | 2007-10-31 | — | — | EP | claimed |
| WO-2006081391-A2 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2006-08-03 | — | — | WO | claimed |
| US-20060173021-A1 | pyrazinyl, pyrimidinyl and pyridazinyl derivatives such asN-[5-(2-Chloro-5-trifluoromethyl-phenyl)-pyrazin-2-yl]-2,6-difluoro-benzamide, used as immunosuppressants for the treatmet or prevent inflammatory and immune disorders | SYNTA PHARMACEUTICALS CORP. (US) | 2006-08-03 | — | — | US | claimed |
| US-9493427-B2 | Compounds for inflammation and immune-related uses | SYNTA PHARMACEUTICALS CORP. (US) | 2016-11-15 | — | — | US | disclosed |
| US-9493427-B2 | Compounds for inflammation and immune-related uses | SYNTA PHARMACEUTICALS CORP. (US) | 2016-11-15 | — | — | US | disclosed |
| EP-1848435-B1 | COMPOUNDS AGAINST INFLAMMATIONS AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP (US) | 2016-01-20 | — | — | EP | disclosed |
| EP-1848435-B1 | COMPOUNDS AGAINST INFLAMMATIONS AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP (US) | 2016-01-20 | — | — | EP | disclosed |
| US-20150266829-A1 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | PRCL Research Inc. (CA) | 2015-09-24 | — | — | US | disclosed |
| US-20150266829-A1 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | PRCL Research Inc. (CA) | 2015-09-24 | — | — | US | disclosed |
| US-8518950-B2 | pyrazinyl, pyrimidinyl and pyridazinyl derivatives such asN-[5-(2-Chloro-5-trifluoromethyl-phenyl)-pyrazin-2-yl]-2,6-difluoro-benzamide, used as immunosuppressants for the treatmet or prevent inflammatory and immune disorders | SYNTA PHARMACEUTICALS CORP. (US) | 2013-08-27 | — | — | US | disclosed |
| US-8518950-B2 | pyrazinyl, pyrimidinyl and pyridazinyl derivatives such asN-[5-(2-Chloro-5-trifluoromethyl-phenyl)-pyrazin-2-yl]-2,6-difluoro-benzamide, used as immunosuppressants for the treatmet or prevent inflammatory and immune disorders | SYNTA PHARMACEUTICALS CORP. (US) | 2013-08-27 | — | — | US | disclosed |
| US-8518950-B2 | pyrazinyl, pyrimidinyl and pyridazinyl derivatives such asN-[5-(2-Chloro-5-trifluoromethyl-phenyl)-pyrazin-2-yl]-2,6-difluoro-benzamide, used as immunosuppressants for the treatmet or prevent inflammatory and immune disorders | SYNTA PHARMACEUTICALS CORP. (US) | 2013-08-27 | — | — | US | disclosed |
| EP-1848435-A2 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | Synta Pharmaceuticals Corporation (US) | 2007-10-31 | — | — | EP | disclosed |
| WO-2006081391-A2 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2006-08-03 | — | — | WO | disclosed |
| WO-2006081391-A2 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2006-08-03 | — | — | WO | disclosed |
| US-20060173021-A1 | pyrazinyl, pyrimidinyl and pyridazinyl derivatives such asN-[5-(2-Chloro-5-trifluoromethyl-phenyl)-pyrazin-2-yl]-2,6-difluoro-benzamide, used as immunosuppressants for the treatmet or prevent inflammatory and immune disorders | SYNTA PHARMACEUTICALS CORP. (US) | 2006-08-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150266829-A1 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | CCR1, CCR9, CXCR2 | IL2 21/4885ABL1 3979/4885FGFR3 1000/4885 |
| US-20130309272-A1 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | CCR1, CCR9, CXCR2 | IL2 22/4885ABL1 4028/4885FGFR3 1023/4885 |
| US-20060173021-A1 | pyrazinyl, pyrimidinyl and pyridazinyl derivatives such asN-[5-(2-Chloro-5-trifluoromethyl-phenyl)-pyrazin-2-yl]-2,6-difluoro-benzamide, used as immunosuppressants for the treatmet or prevent inflammatory and immune disorders | TPMT, IL5, NAT1 | IL2 9/4885ABL1 1154/4885FGFR3 662/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.